Diseembar 2020: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group in desperate need of new and effective treatments.
Natiijooyinkan waxaa lagu soo bandhigay Bulshada Maraykanka ee Hematology's shir sannadeedka 2020 ee casriga ah.
Traditionally, around half of patients with high-risk LBCL, a subgroup of the disease in which patients have double- or triple-hit qanjiro or additional clinical risk factors identified by the International Prognostic Index (IPI), have not achieved long-term disease remission with standard treatment approaches such as chemoimmunotherapy.
This trial represents a step toward making Daaweynta unugyada CAR T a first-line treatment option for patients with aggressive B-cell lymphoma,” said Sattva S. Neelapu, M.D., professor of Lymphoma and Myeloma. “At the moment, patients with newly diagnosed aggressive B-cell lymphoma get chemotherapy for about six months. Daaweynta unugyada CAR T, if successful, may make it a one-time infusion with treatment completed in one month.
Iyada oo ku saleysan cilmi-baarista muhiimka ah ee ZUMA-1, Axi-cel waxay hadda u haysataa shatiga daawaynta dadka soo noqnoqda ama LBCL dib u celinaya kuwaas oo horey u lahaa laba ama in ka badan oo daawaynta habaysan. Tijaabada ZUMA-12 waa wejiga 2-calaamad furan, hal-cudud, tijaabo xarun badan oo dhiseysa natiijooyinka tijaabada ZUMA-1 si loo qiimeeyo isticmaalka axi-cel oo ah daawaynta safka hore ee bukaanka leh LBCL khatarta sare leh. .
Marka loo eego daraasadda ku-meel-gaarka ah ee ZUMA-12, 85 boqolkiiba bukaannada lagu daweeyay axi-cel waxay heleen jawaab celin guud, iyo 74% waxay heleen jawaab dhammaystiran. Ka dib dabagal dhexdhexaad ah oo bilihii 9.3 ah, 70% bukaannada la shaqaaleysiiyay waxay muujiyeen jawaab celin joogta ah oo ku saabsan goynta xogta.
White blood cell count reduction, encephalopathy, anaemia, and cytokine sii daayo syndrome were the most common side effects linked with axi-cel treatment. By the time the data was analysed, all adverse events had been resolved.
Furthermore, when compared to when the immunotherapy products were generated from patients who had already received several lines of chemotherapy, the peak level of CAR T cells present in the blood, as well as the median CAR T cell expansion, were higher in this trial of first-line Daaweynta unugyada CAR T.
"Taam ahaanshaha unugyada T-ga waxaa lagu xiri karaa waxtarka daaweynta weyn, taasoo keentay natiijooyin bukaan oo wanaagsan," Neelapu ayaa ku daray.
Iyadoo la raacayo natiijooyinka ku-meel-gaadhka ah ee wanaagsan ee ZUMA-12, cilmi-baarayaashu waxay qorsheynayaan inay sii wadaan la-socodka bukaannada si loo hubiyo in fal-celintooda daawadu ay tahay mid waara.
“A randomised clinical trial would be required to definitely demonstrate that CAR T cell therapy is superior to existing standard of care with chemoimmunotherapy in these high-risk patients if the responses are persistent after prolonged follow-up,” Neelapu said. It also begs the question of whether CAR T cell treatment should be tested in intermediate-risk patients with big B-cell lymphoma
